News

MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development

April 19, 2022
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development
Read more
MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug Development

Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

February 17, 2022
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic...
Read more
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

Modeling ischemic stroke in a triculture neurovascular unit on-a-chip

December 15, 2021
Scientists from MIMETAS introduce a new neurovascular unit on-a-chip model to study ischemic events in the human brain.
Read more
Modeling ischemic stroke in a triculture neurovascular unit on-a-chip

Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

December 10, 2021
- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met - The triplet combination sho...
Read more
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3 in Patients with Advanced Solid Tumors

December 02, 2021
IND approval enables clinical trial advancement and enrollment of dose expansion cohorts in the US
Read more
InteRNA Technologies Announces U.S. FDA Clearance of  IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3 in Patients with Advanced Solid Tumors

InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board

October 19, 2021
-- Adding deep preclinical and clinical immuno-oncology expertise to expand InteRNA's preclinical pipeline and accelerate clini...
Read more
InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board

InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board

October 12, 2021
Appointment of Andrea van Elsas as a new member of the Company's Supervisory Board.
Read more

Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A

October 07, 2021
Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A
Read more
Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A

Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

October 07, 2021
- Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treate...
Read more
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Sapreme Presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society

September 27, 2021
Sapreme Presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society
Read more
Sapreme Presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society

Home > News

© 2022 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds